Training fellowship awarded to Alzheimer researcher
The American Academy of Neurology (AAN) Foundation and the Alzheimer's Association awarded the 2009 Robert Katzman, M.D., Clinical Research Training Fellowship to Joshua Shulman, M.D., Ph.D., a senior neurology resident at the Brigham and Women's Hospital and the Massachusetts General Hospital, for his work investigating genes that influence risk for Alzheimer's disease. The two-year, $130,000 fellowship will be formally presented during the American Academy of Neurology's 61st Annual Meeting in Seattle, held April 25 through May 2.
The Robert Katzman, M.D., Clinical Research Training Fellowship is designed to encourage Alzheimer's disease clinical research with the goal of providing better treatment, prevention or cure of the disease. Shulman's research is designed to identify genes that influence risk for Alzheimer's disease.
"Common genetic variation influences susceptibility to Alzheimer's disease and age-related cognitive decline," said Shulman. "This research may facilitate early diagnosis and highlight new targets for future therapies. I am honored and deeply grateful to the AAN Foundation and the Alzheimer's Association for supporting my further research training and career development in this important field of neurology."
The fellowship includes tuition reimbursement for education in clinical research methodology.
The American Academy of Neurology
An association of more than 21,000 neurologists and neuroscience professionals, the American Academy of Neurology is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer's disease, narcolepsy, and stroke. For more information about the American Academy of Neurology Foundation, visit www.aan.com/foundation.
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.